Phyton Biotech, a German/North American Plant Cell Fermentation technology company, and AqVida, a German oncology Finished Dosage Formulation (FDF) manufacturer, have received European approval from the European Directorate of Quality Medicines for AqVida's paclitaxel injectable FDF, it was reported yesterday.

According to the strategic partnership agreement with AqVida, Phyton Biotech will be the exclusive supplier of paclitaxel API for AqVida's Taxol generic formulation, which is produced in AqVida's new state-of-the-art injectable manufacturing facility situated in Dassow, Germany. AqVida's ultra-modern robotic manufacturing line, designed for filling cytotoxic injectables, will be used to produce AqVida's generic oncology medicines to treat common types of cancer.

Wolfgang Heinze, chief executive officer (CEO) of AqVida, said, 'We chose to work with Phyton because of the company's superior quality fermentation-produced API, in comparison to naturally extracted or semi-synthetically produced alternatives. Approval of ourpaclitaxel injectable FDF by the European Directorate of Quality Medicines is a major milestone for our company.'